John Reid

John Reid has a diverse and extensive work experience in the field of business development, strategic partnering, and commercialization in the life science industry.

John is currently working as the Chief Business Officer at QurCan Therapeutics Inc., a position they have held since March 2023. Prior to this, they served as the Executive Vice President of Strategic Partnering & Business Development at the same company, starting in April 2021.

Before joining QurCan Therapeutics, John operated their own consultancy called Talking Terms, where they provided business advisory services, executive-in-residence support, and governance services to life science companies and research institutions. Their clients included The Hospital for Sick Children, The University of Toronto, Rosetta Therapeutics, Ontario Genomics, and Nanology Labs. John founded and served as the President of Talking Terms from February 2020 to April 2022.

John also has experience as an Executive In Residence at Rosetta Therapeutics @JLABS from June 2020 to July 2021, where they contributed to the development and growth of the company. John also served as an Executive In Residence at Nanology Labs, focusing on supporting the commercialization of T-MX, a radiosensitizer for cancer solid tumor radiotherapy. In that role, they developed business strategies, identified partnership opportunities, and helped secure seed funding.

Additionally, John worked as a Business Development Consultant at The Hospital for Sick Children from March 2020 to March 2021, where they supported licensing and investment transactions related to an early-stage multibody technology platform and products. Their efforts resulted in Amplitude Ventures licensing the intellectual property and funding the launch of Radiant Biotherapeutics.

From 2014 to 2020, John held the position of Director of Technology Development and Commercialization at the University Health Network, where they implemented a venture model of technology transfer and achieved significant commercialization success. Prior to that, they founded and served as Principal of Entrepid Business Development LLC, providing consulting services in business development and portfolio optimization to biotech, pharma, and universities.

John's earlier experience includes roles at AstraZeneca, where they played key roles in business development, alliance management, strategic planning, and molecular sciences drug discovery. At GlaxoWellcome, they led a research team focusing on signal transduction and published research articles in the field.

Overall, John Reid's work experience demonstrates their expertise in business development, strategic partnerships, commercialization, and technology transfer in the life science industry.

John Reid earned their Ph D in Biology from the University of California, Berkeley, which they attended from 1982 to 1987. John then pursued a Master of Business Administration (M.B.A.) degree in Business Administration, Healthcare Management, Operations, and Finance from Drexel University between 2006 and 2009. John also completed an executive education program in Business Administration and Management, General at The Wharton School from 2003 to 2006. Additionally, John obtained a Bachelor's Degree from the University of California, Davis, although the specific years of study are not provided. There is no information about their educational experience at UCC.